Beyond CTLA-4 and PD-L1/PD1, one target that is actively being studied is the lymphocyte activation gene-3 (LAG-3), which has been associated with the exhaustion of tumour-infiltrating T cells, as a mechanism of resistance to certain immunotherapies. The gene discussed is CTLA4; the disease is neoplasm.